—Attributed to Jean Cocteau
America, Can We Talk?: Dr. Richard Bartlett interview, July 2, 2020: "100% of my patients are alive ... Let me tell you what I've heard from patients when I started using this. They tell me, 'I feel better during the first treatment'. And so their chest pain goes away. Their shortness of breath goes away. Their fever breaks."
NewsWest9: Local doctor believes he has found 'silver bullet' for COVID-19: Dr. Bartlett says COVID-19 starts in the respiratory system but then triggers a severe inflammatory process, called Cytokine Storms, that eventually leads to multi-organ failure and death. But the inhaled steroid helps to prevent that inflammation. "It's like putting out a fire at the base of the fire," Bartlett said. "I'm having patients recover so quick."
CBS7: West Texas doctor claims to have "silver bullet" for COVID-19: "I am not aware of any doctors anywhere that are using this specifically for COVID-19, yet," Bartlett said. Bartlett said he treats people as soon as they show symptoms. "Early treatment is better with this disease," he said. "And I'm having a 100% survival rate. I don't even know how many I've treated...dozens. I have 14 that I'm treating right now." Bartlett said that patients tell him they feel immediate relief.
KHOU-TV: VERIFY: No, this Texas doctor has not discovered a cure for COVID-19 using 'inhaled steroids': The CDC said there is no known cure for COVID-19. So, we can VERIFY that claim is false.
Mark Thornton, M.D.: Cure for Covid? Not So Fast!: I was surprised that people would believe this guy. I was also surprised that someone would put him on television.
Midland Reporter-Telegram: Midland Health: Doctors shouldn't prescribe inhaled steroids for COVID: We have had to persuade multiple patients and their families that the use of Budesonide has no proven benefit and may be harmful in the treatment of COVID-19 infections.
The Times of Israel: Common asthma drug can reduce COVID hospitalizations by 90%: Oxford University researchers say steroid budesonide, inhaled as a treatment for respiratory disorders, effective when administered to patients within a week of first symptoms
The Lancet: Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial: Inhaled budesonide improves time to recovery, with a chance of also reducing hospital admissions or deaths
The Lancet: Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial: Early administration of inhaled budesonide reduced the likelihood of needing urgent medical care and reduced time to recovery after early COVID-19.
/misc | Oct 03, 2021
Subscribe or visit the archives.